PH12012500969A1 - Spiropiperidine compounds as orl-1 receptor antagonists - Google Patents
Spiropiperidine compounds as orl-1 receptor antagonistsInfo
- Publication number
- PH12012500969A1 PH12012500969A1 PH1/2012/500969A PH12012500969A PH12012500969A1 PH 12012500969 A1 PH12012500969 A1 PH 12012500969A1 PH 12012500969 A PH12012500969 A PH 12012500969A PH 12012500969 A1 PH12012500969 A1 PH 12012500969A1
- Authority
- PH
- Philippines
- Prior art keywords
- orl
- treatment
- receptor antagonists
- compounds
- spiropiperidine compounds
- Prior art date
Links
- 108010020615 nociceptin receptor Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010033307 Overweight Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382246 | 2009-11-16 | ||
| US29862910P | 2010-01-27 | 2010-01-27 | |
| PCT/US2010/056180 WO2011060035A1 (en) | 2009-11-16 | 2010-11-10 | Spiropiperidine compounds as orl-1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12012500969A1 true PH12012500969A1 (en) | 2013-01-07 |
Family
ID=41728051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/500969A PH12012500969A1 (en) | 2009-11-16 | 2010-11-10 | Spiropiperidine compounds as orl-1 receptor antagonists |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8232289B2 (https=) |
| EP (1) | EP2501703B1 (https=) |
| JP (1) | JP5680101B2 (https=) |
| KR (1) | KR101363830B1 (https=) |
| CN (1) | CN102612520B (https=) |
| AR (1) | AR078863A1 (https=) |
| AU (1) | AU2010319581C1 (https=) |
| CA (1) | CA2796161C (https=) |
| CO (1) | CO6541545A2 (https=) |
| CR (1) | CR20130087A (https=) |
| DK (1) | DK2501703T3 (https=) |
| DO (1) | DOP2012000135A (https=) |
| EA (1) | EA020848B1 (https=) |
| EC (1) | ECSP12011902A (https=) |
| ES (1) | ES2435814T3 (https=) |
| HN (1) | HN2012001011A (https=) |
| HR (1) | HRP20130967T1 (https=) |
| IL (1) | IL219370A (https=) |
| JO (1) | JO2887B1 (https=) |
| MA (1) | MA33751B1 (https=) |
| ME (1) | ME01537B (https=) |
| MX (1) | MX2012005691A (https=) |
| MY (1) | MY160665A (https=) |
| NZ (1) | NZ600006A (https=) |
| PE (1) | PE20121430A1 (https=) |
| PH (1) | PH12012500969A1 (https=) |
| PL (1) | PL2501703T3 (https=) |
| PT (1) | PT2501703E (https=) |
| RS (1) | RS53018B (https=) |
| SI (1) | SI2501703T1 (https=) |
| TW (1) | TWI465453B (https=) |
| UA (1) | UA107943C2 (https=) |
| WO (1) | WO2011060035A1 (https=) |
| ZA (1) | ZA201202967B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106883246B (zh) * | 2009-12-04 | 2020-05-29 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| US9394290B2 (en) * | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| TWI582096B (zh) * | 2011-12-06 | 2017-05-11 | 美國禮來大藥廠 | 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物 |
| TW201416370A (zh) | 2012-07-31 | 2014-05-01 | Lilly Co Eli | 用於治療焦慮之ｏｒｌ－１受體拮抗劑 |
| CR20190436A (es) | 2012-10-02 | 2019-10-29 | Bayer Cropscience Ag | COMPUESTOS HETEROCICLICOS COMO PLAGUICIDAS (Divisional 2015-0182) |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| JO3638B1 (ar) * | 2015-09-09 | 2020-08-27 | Lilly Co Eli | مركبات مفيدة في تثبيط ror - جاما- t |
| UA125519C2 (uk) | 2016-07-29 | 2022-04-13 | Суновіон Фармасьютікалз Інк. | Сполуки і композиції і їх застосування |
| CA3032141A1 (en) | 2016-07-29 | 2018-02-01 | Vadim ALEXANDROV | Compounds and compositions and uses thereof |
| IL268694B2 (en) | 2017-02-16 | 2023-10-01 | Sunovion Pharmaceuticals Inc | Treatment of schizophrenia |
| DK3589637T3 (da) * | 2017-03-02 | 2021-06-14 | Lilly Co Eli | Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T |
| PL3589638T3 (pl) | 2017-03-02 | 2021-09-27 | Eli Lilly And Company | Związki użyteczne do hamowania ror-gamma-t |
| BR112020001433A2 (pt) | 2017-08-02 | 2020-07-28 | Sunovion Pharmaceuticals Inc. | compostos de isocromano e usos dos mesmos |
| EA202091945A1 (ru) | 2018-02-16 | 2021-01-18 | Суновион Фармасьютикалз Инк. | Соли, кристаллические формы и способы их получения |
| TWI848031B (zh) | 2018-12-17 | 2024-07-11 | 美商維泰克斯製藥公司 | Apol1抑制劑及其使用方法 |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| CN115734785A (zh) | 2020-04-14 | 2023-03-03 | 桑诺维恩药品公司 | (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症 |
| WO2021252863A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and using the same |
| IL300298B2 (en) | 2020-08-26 | 2025-06-01 | Vertex Pharma | Inhibitors of apol1 and methods of using same |
| CN119343353A (zh) * | 2022-02-08 | 2025-01-21 | 弗特克斯药品有限公司 | 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| US6686370B2 (en) * | 1999-12-06 | 2004-02-03 | Euro-Celtique S.A. | Triazospiro compounds having nociceptin receptor affinity |
| KR100628292B1 (ko) * | 2001-04-18 | 2006-09-27 | 유로-셀티크 소시에떼 아노뉨 | 스파이로파이라졸 화합물 |
| WO2002088089A1 (en) | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
| WO2003010168A1 (fr) * | 2001-07-23 | 2003-02-06 | Banyu Pharmaceutical Co., Ltd. | Derive de 4-oxoimidazolidine-2-spiropiperidine |
| WO2003064425A1 (en) * | 2002-01-28 | 2003-08-07 | Pfizer Japan Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| AU2003235912A1 (en) | 2002-05-10 | 2003-11-11 | Taisho Pharmaceutical Co., Ltd. | Spiro-ring compound |
| US6995168B2 (en) * | 2002-05-31 | 2006-02-07 | Euro-Celtique S.A. | Triazaspiro compounds useful for treating or preventing pain |
| NZ538307A (en) * | 2002-09-09 | 2008-04-30 | Janssen Pharmaceutica Nv | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| CA2563164A1 (en) * | 2004-03-29 | 2005-10-06 | Pfizer Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
| DE102004039382A1 (de) * | 2004-08-13 | 2006-02-23 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| AU2009228647B2 (en) * | 2008-03-27 | 2013-07-04 | Grunenthal Gmbh | Substituted spirocyclic cyclohexane derivatives |
-
2010
- 2010-10-11 UA UAA201205367A patent/UA107943C2/uk unknown
- 2010-11-02 AR ARP100104035A patent/AR078863A1/es active IP Right Grant
- 2010-11-03 JO JO2010386A patent/JO2887B1/en active
- 2010-11-05 TW TW099138241A patent/TWI465453B/zh not_active IP Right Cessation
- 2010-11-10 SI SI201030388T patent/SI2501703T1/sl unknown
- 2010-11-10 MY MYPI2012002117A patent/MY160665A/en unknown
- 2010-11-10 WO PCT/US2010/056180 patent/WO2011060035A1/en not_active Ceased
- 2010-11-10 DK DK10782482.3T patent/DK2501703T3/da active
- 2010-11-10 ES ES10782482T patent/ES2435814T3/es active Active
- 2010-11-10 ME MEP-2013-118A patent/ME01537B/me unknown
- 2010-11-10 CN CN201080051850.4A patent/CN102612520B/zh not_active Expired - Fee Related
- 2010-11-10 PH PH1/2012/500969A patent/PH12012500969A1/en unknown
- 2010-11-10 EP EP10782482.3A patent/EP2501703B1/en active Active
- 2010-11-10 PT PT107824823T patent/PT2501703E/pt unknown
- 2010-11-10 KR KR1020127012498A patent/KR101363830B1/ko not_active Expired - Fee Related
- 2010-11-10 HR HRP20130967AT patent/HRP20130967T1/hr unknown
- 2010-11-10 MX MX2012005691A patent/MX2012005691A/es active IP Right Grant
- 2010-11-10 JP JP2012538935A patent/JP5680101B2/ja not_active Expired - Fee Related
- 2010-11-10 PL PL10782482T patent/PL2501703T3/pl unknown
- 2010-11-10 US US12/943,187 patent/US8232289B2/en not_active Expired - Fee Related
- 2010-11-10 AU AU2010319581A patent/AU2010319581C1/en not_active Ceased
- 2010-11-10 NZ NZ600006A patent/NZ600006A/en not_active IP Right Cessation
- 2010-11-10 PE PE2012000659A patent/PE20121430A1/es active IP Right Grant
- 2010-11-10 CA CA2796161A patent/CA2796161C/en not_active Expired - Fee Related
- 2010-11-10 RS RS20130485A patent/RS53018B/sr unknown
- 2010-11-10 EA EA201290352A patent/EA020848B1/ru not_active IP Right Cessation
-
2012
- 2012-04-23 IL IL219370A patent/IL219370A/en not_active IP Right Cessation
- 2012-04-23 ZA ZA2012/02967A patent/ZA201202967B/en unknown
- 2012-05-04 CO CO12073055A patent/CO6541545A2/es active IP Right Grant
- 2012-05-11 HN HN2012001011A patent/HN2012001011A/es unknown
- 2012-05-11 DO DO2012000135A patent/DOP2012000135A/es unknown
- 2012-05-14 MA MA34869A patent/MA33751B1/fr unknown
- 2012-05-16 EC ECSP12011902 patent/ECSP12011902A/es unknown
-
2013
- 2013-02-26 CR CR20130087A patent/CR20130087A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012500969A1 (en) | Spiropiperidine compounds as orl-1 receptor antagonists | |
| PT2501704E (pt) | Compostos de espiropiperidina como antagonistas do receptor orl-1 | |
| UA102857C2 (en) | Quinuclidine carbonate derivatives and use thereof | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
| MX352881B (es) | Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2. | |
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| UA107334C2 (ru) | Производные аминоэфиров алкалоидов и их лекарственные композиции | |
| MY165113A (en) | Piperidinone carboxamide azaindane cgrp receptor antagonists | |
| IN2012DN02735A (https=) | ||
| IN2012DN00754A (https=) | ||
| PH12015501289B1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
| MY172809A (en) | Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse | |
| PH12012502300A1 (en) | Nicotinic receptor non-competitive antagonists | |
| TN2012000207A1 (en) | Spiropiperidine compounds as orl-1 receptor antagonists | |
| WO2009108635A3 (en) | Novel compositions for treatment of diseases related to activated lymphocytes | |
| CL2012001262A1 (es) | Compuestos derivados de espiropiperidina; composicion farmaceutica; y uso como antagonistas del receptor orl-1 en el tratamiento de la depresion, migraña, obesidad. | |
| CY1114664T1 (el) | Ενωσεις σπιροπιπεριδινης ως ανταγωνιστες υποδοχεα orl-1 | |
| TN2011000063A1 (en) | Quinuclidine carbonate derivatives and medicinal composition thereof | |
| UA96037C2 (ru) | Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия | |
| TN2013000179A1 (en) | Piperidinone carboxamide azaindane cgrp receptor antagonists | |
| PH12013501453A1 (en) | Nicotinic receptor non-competitive antagonists | |
| UA96048C2 (ru) | Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия | |
| UA59517U (ru) | Фармацевтическая композиция для лечения больных опиоидной зависимостью |